Amiodarone reduces depolarization-evoked glutamate release from hippocampual synaptosomes

J Pharmacol Sci. 2017 Mar;133(3):168-175. doi: 10.1016/j.jphs.2017.02.014. Epub 2017 Mar 8.

Abstract

Decreased brain glutamate level has emerged as a new therapeutic approach for epilepsy. This study investigated the effect and mechanism of amiodarone, an anti-arrhythmic drug with antiepileptic activity, on glutamate release in the rat hippocampus. In a synaptosomal preparation, amiodarone reduced 4-aminopyridine-evoked Ca2+-dependent glutamate release and cytosolic Ca2+ concentration elevation. Amiodarone did not affect the 4-aminopyridine-evoked depolarization of the synaptosomal membrane potential or the Na+ channel activator veratridine-evoked glutamate release, indicating that the amiodarone-mediated inhibition of glutamate release is not caused by a decrease in synaptosomal excitability. The inhibitory effect of amiodarone on 4-aminopyridine-evoked glutamate release was markedly decreased in synaptosomes pretreated with the Cav2.2 (N-type) and Cav2.1 (P/Q-type) channel blocker ω-conotoxin MVIIC, the calmodulin antagonists W7 and calmidazolium, or the protein kinase A inhibitors H89 and KT5720. However, the intracellular Ca2+-release inhibitors dantrolene and CGP37157 had no effect on the amiodarone-mediated inhibition of glutamate release. Furthermore, amiodarone reduced the frequency of miniature excitatory postsynaptic currents without affecting their amplitude in hippocampal slices. Our data suggest that amiodarone reduces Ca2+ influx through N- and P/Q-type Ca2+ channels, subsequently reducing the Ca2+-calmodulin/protein kinase A cascade to inhibit the evoked glutamate release from rat hippocampal nerve terminals.

Keywords: Amiodarone; Ca(2+) channels; Glutamate release; Hippocampus; Synaptosomes.

MeSH terms

  • 4-Aminopyridine / pharmacology
  • Amiodarone / pharmacology*
  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Aspartic Acid / pharmacology
  • Calcium / physiology
  • Calcium Channel Blockers / pharmacology
  • Calmodulin / antagonists & inhibitors
  • Capsaicin / pharmacology
  • Carbazoles / pharmacology
  • Glutamic Acid / metabolism*
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • Hippocampus / physiology
  • Imidazoles / pharmacology
  • Isoquinolines / pharmacology
  • Macrolides / pharmacology
  • Male
  • Membrane Potentials / drug effects
  • Protein Kinase Inhibitors / pharmacology
  • Pyrroles / pharmacology
  • Rats, Sprague-Dawley
  • Sulfonamides / pharmacology
  • Synaptosomes / drug effects*
  • Synaptosomes / metabolism
  • Synaptosomes / physiology
  • omega-Conotoxins / pharmacology

Substances

  • Anti-Arrhythmia Agents
  • Calcium Channel Blockers
  • Calmodulin
  • Carbazoles
  • Imidazoles
  • Isoquinolines
  • Macrolides
  • Protein Kinase Inhibitors
  • Pyrroles
  • Sulfonamides
  • benzyloxyaspartate
  • omega-Conotoxins
  • Aspartic Acid
  • Glutamic Acid
  • calmidazolium
  • KT 5720
  • W 7
  • bafilomycin A1
  • 4-Aminopyridine
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • Amiodarone
  • Capsaicin
  • Calcium